Abpro Holdings Inc
ABPWW
Other OTC0.00
USD
- -
- -
CIK
0001893219
ISIN
US0008471114
CUSIP
000847111
Return %
Stock
S&P500
1Y
-91.33
19.01
3Y
-93.50
65.48
5Y
-93.50
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jin Wook Suk
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 Summit Drive Burlington MA United States of America 01801
- IPO Date
- Mar 9, 2022
- CIK
- 0001893219
- Website
- abpro.com
- Similar Companies
- Business
- Abpro Holdings, Inc. operates as a biotechnology company focused on developing next-generation antibody therapeutics aimed at improving the lives of patients with severe and life-threatening diseases. The company specializes in novel antibody constructs primarily for immuno-oncology and ophthalmology applications. Its core product offerings include antibody drug candidates such as ABP-102, a tetravalent bispecific HER2 x CD3 T-cell engager designed for the treatment of HER2-positive solid tumors including breast, gastric, and pancreatic cancers; and ABP-201, an antibody that simultaneously inhibits VEGF and ANG-2 for treating vascular diseases of the eye, such as diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Abpro utilizes proprietary DiversImmune® and MultiMab™ platforms for antibody discovery and engineering, enabling the creation of diverse and fit-for-purpose multimodal antibody therapies. In recent years, Abpro Holdings has undergone significant corporate restructuring, including the completion of a business combination with Atlantic Coastal Acquisition Corp. II in November 2024, which resulted in the formation of the current holding company structure and listing on Nasdaq under the tickers ABP and ABPWW. This merger involved the issuance of approximately 50 million shares valued at roughly $500 million. Following the merger, Abpro entered into a strategic partnership with Celltrion, which funds all development expenses for ABP-102 and supports worldwide development and commercialization efforts. The company also completed a 1-for-30 reverse stock split in late 2025 to maintain Nasdaq compliance. Operational efficiencies have been advanced through an estimated 60% reduction in operating costs to support a capital-efficient growth phase. Clinical trials for ABP-102 are anticipated to begin in the first half of 2026, supported by successful preclinical data presented at major scientific conferences. Abpro Holdings targets global markets including the United States, Asia, and other regions through its collaborations and direct operations. Founded originally as Abpro Corporation and headquartered in Woburn, Massachusetts, the company operates as a holding entity with Abpro Corporation as its wholly owned subsidiary. Abpro’s pipeline focuses on treatments for various cancers (HER2-positive breast, gastric, pancreatic; non-HER2 gastric and liver cancers), ophthalmologic conditions (wet AMD and DME), and infectious diseases. Recent leadership changes include the appointment of Miles Suk as CEO in 2025, alongside continued strategic emphasis on advancing its next-generation antibody therapeutics pipeline through proprietary platforms and external partnerships. This comprehensive positioning consolidates Abpro Holdings as a biotechnology firm advancing innovative, multispecific antibody constructs for immuno-oncology and eye diseases with a robust pipeline, significant financial backing, major strategic alliances, and active clinical development programs geared toward commercialization beginning in the mid-2020s.